Donald W. DeGolyer - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 16 Sep 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2022, 18:00:12 UTC
Prior SEC filing: 29 Aug 2022
Next SEC filing: 05 Oct 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Richard Cunningham as attorney-in-fact for Donald W. DeGolyer

Key filing fact

Donald W. DeGolyer filed Form 4 for TYME TECHNOLOGIES, INC. on 16 Sep 2022.

Key facts

This page summarizes Donald W. DeGolyer's Form 4 filing for TYME TECHNOLOGIES, INC..
6 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 16 Sep 2022, 18:00.

Change

Previous filing in this sequence was filed on 29 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -100,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $2.90
Footnotes: F1

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -50,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $2.33
Footnotes: F2

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -50,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $1.18
Footnotes: F3

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -65,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $1.22
Footnotes: F4

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -88,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 88,000
Exercise price: $1.10
Footnotes: F5

TYME transaction Derivative

Director Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -88,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 88,000
Exercise price: $0.3100
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Donald W. DeGolyer is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 4,382 shares of Syros common stock for $66.18 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").

Footnote F2

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.

Footnote F3

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.

Footnote F4

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.

Footnote F5

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.

Footnote F6

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.